Welcome to the e-CCO Library!

DOP006: Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sigall Boneh R.1, Levine A.1,2, Lomer M.3, Wierdsma N.4, Alan P.5, Fiorino G.6, Gatti S.7, Jonkers D.8, Kierkus J.9, Katsanos K.H.10, Melgar S.11, Saritas Yuksel E.12, Whelan K.13, Wine E.14, Gerasimidis K.*15

Created: Wednesday, 20 February 2019, 10:36 AM
DOP006: Research gaps in diet and nutrition in Inflammatory Bowel Disease. A topical review by ECCO
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gerasimidis K.
environmental factors, Macrobiota, Anaemia, iron deficiency, Exclusive enternal nutrition, FODMAP
Files: 1
DOP007: Crohn's disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN). Microbiome changes of a randomized clinical trial (RCT) in pediatric CD: remission is associated with similar structural + functional profiles
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dunn K.A.1, Sigall-Boneh R.2, Bielawski J.P.1, Turner D.3, Van Limbergen J.*4, Levine A.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Bor1*, F. Klaudia2, P. Miheller3, K. Palatka4, T. Szamosi5, Á. Vincze6, M. Rutka7, K. Szántó2, A. Bálint2, Z. Szepes2, F. Nagy2, Á. Milassin2, A. Fábián2, Á. Csontos3, P. Golovics5, L. Lakner8, K. Müllner3, M. Papp9, Á. Salamon10, K. Sarang8, Z. Vitális4, E. Schafer11, P. Sarlós6, T. Molnár2

Created: Thursday, 21 February 2019, 9:14 AM
DOP007: Interleukin-10 inhibits human IFN#CHR:gamma_LOWER# and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
Year: 2016
Source: ECCO'16 DOP
Authors: Veenbergen S.
dendritic cell, Crohn's Disease, lymphocyte, mucosal immunology
Files: 1
DOP007: Interleukin-10 inhibits human IFNγ and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Veenbergen*1, P. Li2, H. Raatgeep1, D. Lindenbergh-Kortleve1, L. de Ruiter1, M. van Leeuwen1, D. Winter3, Y. Simons-Oosterhuis1, L. van Berkel1, S. Nugteren1, J. Arnold1, Y. Wakabayashi4, J. Zhu4, L. de Ridder3, G. Driessen5, J. Escher3, W. Leonard2, J. Samsom1

Created: Friday, 22 February 2019, 9:49 AM
DOP008: Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Svolos V.1, Hansen R.2, Ijaz U.Z.3, Quince C.4, Watson D.5, Alghamdi A.5, Brejnrod A.4, Ansalone C.6, Milling S.6, Gaya D.7, Russell R.2, Gerasimidis K.*1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP008: Dietary manipulation of the healthy human and Colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gerasimidis K.
environmental factors, Microbiota, Exclusive enternal nutrition
Files: 1
DOP008: Human intestinal V#CHR:delta_LOWER#2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
Year: 2016
Source: ECCO'16 DOP
Authors: McCarthy N.
Crohn's Disease, Ulcerative Colitis, Lymphocyte, mucosal immunology, vedolizumab
Files: 1
DOP008: Human intestinal Vδ2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Tyler1, N. McCarthy*2, B. Moser1, A. Stagg2, M. Eberl1, J. Lindsay2, 3

Created: Friday, 22 February 2019, 9:49 AM
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registry
Year: 2018
Source: ECCO'18 Vienna
Authors: Turner Dan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Turner1*, S. Koletzko2, H. Winter3, R. Baldassano4, M. Dubinsky5, W. Faubion6, J. Hyams7, S. Kugathasan8, J. Rosh9, J. Escher10, A. Griffiths11, J. Kierkus12, R. Russell13, G. Heap14, D. Arikan14, V. Kuehnl15, J. Petersson14, A. Robinson16, F. Ruemmele17

Created: Thursday, 21 February 2019, 9:14 AM
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Spalinger*1, S. Kasper1, C. Gottier1, S. Lang1, M. Fried1, 2, G. Rogler1, 2, M. Scharl1, 2

Created: Friday, 22 February 2019, 9:49 AM
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Spalinger M.
cancer in IBD, IBD, microbiota, lymphocyte, genetics
Files: 1
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cohen-Dolev N.*1, Sladek M.2, Sigall Boneh R.1, Veres G.3, Hussey S.4, Staiano A.5, Nuti F.6, Lionetti P.7, Koletzko S.8, Levine A.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Cohen-Dolev N.
Crohn's disease, Corticosteroid, Exclusive enteral nutrition
Files: 1
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Lukin1, A. Weiss1, S. Aniwan2, S. Kadire3, G. Tran3, M. Rahal3, D. Faleck4, A. Winters4, S. Chablaney4, J. Meserve5, G. Kochhar6, P. Shashi6, J.L. Koliani-Pace7, M. Bohm3, S.V. Sagi3, M. Fischer3, B. Boland5, S. Singh5, R. Hirten4, E. Shmidt4, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen6, B.E. Sands4, W.J. Sandborn5, J.-F. Colombel4, C.A. Siegel7, P.S. Dulai5*

Created: Thursday, 21 February 2019, 9:14 AM